ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION?
https://doi.org/10.20996/1819-6446-2016-12-2-191-195
Abstract
Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic events) are discussed. The authors briefly present subanalysis of ARISTOTLE study, which compares the efficacy and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic heart disease.
About the Authors
D. A. Napalkov
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
A. A. Sokolova
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
A. V. Rodionov
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
References
1. Thompson PL, Verheugt WAV. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther 2014; 36: 1176-81.
2. Antithrombotic Triallist’s Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC Guidelines on the management of the stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
4. Steg PG, James SK, Atar D et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
5. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention; a randomized controlled trial. JAMA 2002; 288: 2411-20.
6. Chen ZM, Jiang LX, Chen YP et al. Additon of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21.
7. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet 2013; 381: 1107-15.
8. Fox KA. Dual or single antiplatelet therapy with anticoagulation? Lancet 2013; 381: 1080-81.
9. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; doi: 10.1093/europace/euv309.
10. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577-1585.
11. Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol 2013; 170: 215-220.
12. Rao MP, Pokorney SD, Granger CB. Atrial fibrillation: a review of recent studies with the focus on those from the Duke clinical research institute. Scientifica (Cairo) 2014; 2014:901586.
Review
For citations:
Napalkov D.A., Sokolova A.A., Rodionov A.V. ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Rational Pharmacotherapy in Cardiology. 2016;12(2):191-195. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-191-195
Views:
2123
.jpg)
Email this article 